Stock listing

Atara Biotherapeutics, Inc.

Selected listing: AT20 · SWB · EUR · DE

Atara Biotherapeutics, Inc. (Stuttgart:AT20), Health Technology. Latest release Sep 30, 2026: Atara Biotherapeutics Reports that the Tabelecleucel Biologics…

AT20:SWBEURDEUpdated October 2, 2026

Ticker: Stuttgart:AT20
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: Stuttgart
Currency: EUR

Latest news from Atara Biotherapeutics, Inc.

Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration

September 30, 2026

Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration

September 29, 2026

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress

August 12, 2026

Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress

May 12, 2026

Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx

April 1, 2026

All Atara Biotherapeutics, Inc. news →

Events

Replays

Atara Biotherapeutics, Inc. (ATRA) Q3 2023 Earnings Call
Wed, Nov 01, 2023 · 09:00 AM ET
Watch
Atara Biotherapeutics, Inc. (ATRA) Q3 2022 Earnings Call
Tue, Nov 08, 2022 · 04:30 PM ET
Watch
Atara Biotherapeutics, Inc. (ATRA) Q2 2022 Earnings Call
Mon, Aug 08, 2022 · 04:30 PM ET
Watch

Research Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. company profile

View the public company page for Atara Biotherapeutics, Inc. on 6ix.

Atara Biotherapeutics, Inc. news

Read company news and market updates connected to Atara Biotherapeutics, Inc..

Atara Biotherapeutics, Inc. investor events

Find investor webinars, events, and replay context for Atara Biotherapeutics, Inc..